Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immix Biopharma, Inc. - Common Stock
(NQ:
IMMX
)
9.100
+0.530 (+6.18%)
Streaming Delayed Price
Updated: 10:54 AM EDT, Mar 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immix Biopharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Immix Biopharma to Participate in Upcoming Investor Conferences
March 03, 2026
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
January 28, 2026
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities
↗
January 12, 2026
Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new shelf registration statement.
Via
Benzinga
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 09, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar
↗
December 08, 2025
Market-based odds now show an 87% chance of a rate cut.
Via
Stocktwits
Topics
ETFs
Economy
Government
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
December 07, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
December 07, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
November 12, 2025
Via
Benzinga
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
November 12, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
November 07, 2025
Via
Benzinga
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
November 03, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
October 14, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
October 06, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
October 01, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
September 18, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
September 11, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 08, 2025
Via
Benzinga
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
September 08, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
August 25, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Other Serious Diseases Strategy
August 06, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion
July 11, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
July 07, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Attends FDA CEO Forum in Washington DC
June 06, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
June 03, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session.
↗
May 29, 2025
Discover the stocks with unexpected trading volume in today's session on the US markets.
Via
Chartmill
On Tuesday, there are stocks with unusual volume. Let's take a look.
↗
May 27, 2025
Volume analysis on 2025-05-27: stocks with an unusual volume in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
↗
May 23, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
↗
May 23, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
May 23, 2025
From
Immix Biopharma, Inc.
Via
GlobeNewswire
Discover the top movers in Friday's pre-market session.
↗
May 23, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
